Table 1 Characteristics of the patients and changes of their weight during the study. Both individual and mean weight changes are presented. p-values are based on paired samples tests for the patients who have completed the corresponding follow-up interval. The dose of topiramate is the highest dose reached. Under "Concomitant medication" the drugs that are undelined were exchanged with topiramate.
Patient N | Gender | Age | DSM-IV | Concomitant medication | Topiramate dose (mg) | Start | Weight change from start (months) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Â | Â | Â | BMI (kg/m2) | weight (kg) | 3 months | 6 months | 9 months | 12 months |
1 | f | 49 | UD | Nortryptiline, carbamazepine | 600 | 42.4 | 110 | -8 | -10 | -11 | -12.5 |
2 | f | 48 | BPI | Risperidone, lamotrigine, lofepramine | 400 | 37.2 | 87 | -9.5 | -14 | -12 | -8 |
3 | f | 49 | BPI | Quetiapine, mirtazapine, lithium, venlafaxine | 200 | 42.3 | 99 | -1 | -5 | -11 | -14 |
4 | m | 50 | BPII | Lithium, paroxetine | 300 | 47.7 | 146 | -10.5 | -21 | -26 | -12.5 |
5 | f | 28 | BPI | Lithium | 200 | 31.5 | 79 | -6 | -10.5 | Â | Â |
6 | m | 31 | BPII | Lithium, reboxetine, trazodone, valproate | 300 | 40.5 | 120 | -6 | -7.5 | -6.5 | -8 |
7 | m | 40 | BPI | Olanzapine, fluoxetine | 400 | 30.3 | 102.5 | -1 | +5 | -1.5 | -5.5 |
8 | f | 41 | BPII | Fluphenazine, carbamazepine, paroxetine | 250 | 34.7 | 90 | -7 | -14 | -18 | -22.5 |
9 | f | 70 | UD | Mirtazapine, lithium, amisulpride, venlafaxine | 200 | 44.4 | 116.5 | -3 | -4 | -4 | -4 |
10 | f | 54 | BPII | Lithium, clomipramine, flupenthixol, trazodone | 250 | 34.7 | 80 | -1.5 | -2.5 | -2 | +0.5 |
11 | f | 48 | UD | Phenelzine, amisulpride, valproate | 250 | 31.0 | 88.5 | -3.5 | -8.5 | Â | Â |
12 | m | 33 | BPI | Lithium, carbamazepine | 200 | 38.7 | 134 | -2.5 | -1 | Â | Â |
Mean reduction (kg) | 4.96 | 7.75 | 10.2 | 9.61 | |||||||
SD | 3.33 | 6.9 | 7.98 | 6.69 | |||||||
p-value | 0.001 | 0.003 | 0.005 | 0.003 | |||||||